7,262 results match your criteria Thyroid Medullary Carcinoma


Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and effects of thyroid diseases.

Clin Chem Lab Med 2019 Feb 22. Epub 2019 Feb 22.

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.

Background There is only limited information on serum reference ranges of calcitonin (CT) in infants, children and adolescents. This gap hampers valid diagnostics in patients with multiple endocrine neoplasia type 2 (MEN 2) and planned prophylactic thyroidectomy. In addition, age-dependent reference ranges for CT are necessary to define a cure in medullary thyroid carcinoma (MTC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2018-1186DOI Listing
February 2019

The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.

Tumori 2019 Feb 19:300891619829571. Epub 2019 Feb 19.

2 Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Purpose:: Two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, have been approved for recurrent/metastatic (R/M) medullary thyroid carcinoma (MTC). To date, it is still debated when and which TKI has to be started in R/M MTC patients. This is due to 1) TKI-related toxicity burden, 2) no overall survival benefit for either TKI, and 3) progression-free survival improvement in MTC subgroups ( RETM918T and RAS mutations) treated with cabozantinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300891619829571DOI Listing
February 2019

Prophylactic thyroidectomy in multiple endocrine neoplasia type 2.

Expert Rev Endocrinol Metab 2010 Nov;5(6):867-874

a Endocrine Practice and Molecular Laboratory, Brückenstr. 21, 69120 Heidelberg, Germany.

Medullary thyroid carcinoma (MTC) is the main component of the autosomal dominant cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). MEN 2 is caused by autosomal dominant gain-of-function mutations in the RET proto-oncogene. In RET-mutation carriers, an age-related progression has been documented from normal C-cells to premalignant C-cell hyperplasia and finally to MTC with or without cervical lymph node metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.10.58DOI Listing
November 2010

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study.

Endocr Connect 2019 Feb 1. Epub 2019 Feb 1.

A Maia, INTERNAL MEDICINE, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, Porto Alegre, 90035-003, Brazil.

Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant genetic disease caused by RET gene germline mutations that is characterized by medullary thyroid carcinoma (MTC) associated with other endocrine tumours. Several reports have demonstrated that the RET mutation profile may vary according to geographical area. In this study we collected clinical and molecular data from 554 patients with surgically confirmed MTC from 176 families with MEN2 in 18 different Brazilian centers to compare the type and prevalence of RET mutations with those from other countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0506DOI Listing
February 2019
1 Read

Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers.

Thyroid 2019 Feb 12. Epub 2019 Feb 12.

The Ohio State University, Department of Cancer Biology and Genetics, Columbus, Ohio, United States ;

Background: Inactivation of DNA mismatch repair (MMR) and the resulting microsatellite instability (MSI) are frequently observed in endometrial, stomach and colorectal cancers as well as more rarely in other solid tumor types. The prevalence of MSI in thyroid cancer has not been explored in-depth, although recent studies utilizing data from large cancer sequencing efforts such as The Cancer Genome Atlas indicate MSI is absent or at least very rare in the most common and most well-studied histologic subtype, papillary carcinoma. In this study, we aim to determine the prevalence of MSI in thyroid cancer by using a large series comprising all major histological subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2018.0655DOI Listing
February 2019
1 Read
4.493 Impact Factor

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples.

J Labelled Comp Radiopharm 2019 Feb 11. Epub 2019 Feb 11.

Dept. of Nuclear Medicine, Medical University Innsbruck, Austria.

With the development of ever more radiopharmaceuticals suitable for theranostic applications, translation of novel compounds from the preclinical stage towards clinical application becomes a bottleneck for the advances in Nuclear Medicine. This review article summarizes the current regulatory framework for clinical trials with radiopharmaceuticals in the European Union, provides a general overview of the documentation required and addresses quality, safety and clinical aspects to be considered. By using a recent successful example of translating a theranostic peptide radioligand, namely In-CP04, which targets receptors expressed in medullary thyroid carcinoma, the pathway from the preclinical development over establishing the required pharmaceutical documentation to designing and submitting a clinical trial is reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jlcr.3712DOI Listing
February 2019
1 Read

[Familial medullary thyroid carcinoma: case report and literature review.]

Rev Fac Cien Med Univ Nac Cordoba 2018 12 12;75(4):303-309. Epub 2018 Dec 12.

Instituto Nacional de Enfermedades Neoplásicas Universidad Nacional Mayor de San Marcos.

Medullary thyroid carcinoma (MTC) is a malignant tumour of the calcitonin-secreting parafollicular C cells of the thyroid gland. Up to 25% of MTC are associated to pathogenic germinal variants on the proto-oncogene RET (locus 10q11.2), which cause Familial Medullary Thyroid Carcinoma (FMTC) or Multiple Endocrine Neoplasia type 2 (MEN2); genetic conditions inherited with autosomal dominant pattern. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31053/1853.0605.v75.n4.20947DOI Listing
December 2018
1 Read

Compact buds with biphasic differentiation and calcitonin-expressing neuroendocrine cells-previously unrecognized structures of thyroglossal duct unveiled by immunohistochemistry.

Virchows Arch 2019 Feb 7. Epub 2019 Feb 7.

Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.

Immunophenotype of thyroglossal duct (TGD) cysts, including lining epithelium and thyroid remnants, is scarcely addressed in the literature. There is indirect evidence that C cells may be derived from progenitor cells of the midline thyroid primordium. This is supported by the recent concept of the endodermal origin of lateral thyroid anlagen and several case reports. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-019-02536-6DOI Listing
February 2019
1 Read

[A review on the RET proto-oncogene mutation in medullary thyroid carcinoma].

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018 Nov;32(22):1754-1758

Medullary thyroid carcinoma(MTC) is a special type of neuroendocrine tumor originated from C-cells of the thyroid gland, MTC can be divided into sporadic(70%-80%)and hereditary(20%-30%), about 98% of the hereditary MTC patients have RET proto-oncogene germline mutation in exon 10, 11, 13, 14, 15, 16. The mutation of RET proto oncogene is closely related to the pathogenesis of MTC, and different mutation of RET proto oncogene exon may lead to different MTC phenotypes.More than 100 kinds of mutations in the RET gene were reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13201/j.issn.1001-1781.2018.22.018DOI Listing
November 2018

Plasmacytoid morphology of poorly differentiated thyroid carcinoma: diagnostic approach with brief review of literature.

Cytopathology 2019 Feb 3. Epub 2019 Feb 3.

Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry.

Poorly differentiated thyroid carcinoma (PDTC) is an uncommon neoplasm of thyroid accounting for 4-7% of all thyroid neoplasm's (1) that are rarely diagnosed accurately on cytology. Medullary thyroid carcinoma (MTC) is the most frequent primary thyroid neoplasm manifesting with plasmacytoid morphology possibly followed by Hürthle neoplasm (HCN) because of their high incidence compared to other subtypes of malignancy. The plasmacytoid morphology in other primary thyroid neoplasms is uncommon and distinguishing such neoplasm's from MTC is crucial for the clinical management of patients presenting with neoplastic thyroid nodules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12681DOI Listing
February 2019
1 Read
1.481 Impact Factor

Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.

Oncotarget 2018 Dec 28;9(102):37662-37675. Epub 2018 Dec 28.

Department of Surgery, The University of Alabama, Birmingham, AL, USA.

Medullary thyroid carcinoma (MTC) is a slow growing neuroendocrine (NE) tumor for which few treatment options are available. Its incidence is rising and mortality rates have remained unchanged for decades. Increasing the repertoire of available treatments is thus crucial to manage MTC progression. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26480
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340867PMC
December 2018
6 Reads

Revisiting the Significance of Prominent C Cells in the Thyroid.

Endocr Pathol 2019 Jan 29. Epub 2019 Jan 29.

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, 2065, Australia.

C cell hyperplasia is considered a precursor lesion for hereditary forms of medullary thyroid carcinoma. It has therefore been suggested as a morphological marker to distinguish hereditary from sporadic medullary thyroid carcinoma and to triage genetic testing in resource poor settings. However, numerous definitions for C cell hyperplasia have been suggested, and there is surprisingly little data regarding the number of C cells present in thyroid glands removed for conditions other than medullary carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12022-019-9567-6DOI Listing
January 2019
1 Read

Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Population-Based Studies.

Am J Epidemiol 2019 Jan 25. Epub 2019 Jan 25.

Division of Epidemiology, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, Utah.

When recruiting research participants through central cancer registries, high response fractions help ensure population-based representation. Using data from 17 recruitment efforts undertaken by the Utah Cancer Registry from 2007 to 2016, we conducted multivariable mixed effects logistic regression to identify case and study characteristics associated with making contact and obtaining cooperation of Utah cancer cases for the following studies: A Population-Based Childhood Cancer Survivor Cohort Study in Utah, Comparative Effectiveness Analysis of Surgery and Radiation for Prostate Cancer (CEASAR Study), Costs and Benefits of Follow-up Care for Adolescent and Young Adult Cancers, Genetic Analysis of Digestive Cancers, Genetic Epidemiology of Breast Cancer, Genetic Epidemiology of Chronic Lymphocytic Leukemia, Genetic Epidemiology of Multiple Myeloma, Head and Neck Cancer Susceptibility Genes, Impact of Remote Familial Colorectal Cancer Risk Assessment and Counseling (Family CARE Project), Medullary Thyroid Carcinoma (MTC) Surveillance Study Osteosarcoma Surveillance Study, the Prostate Cancer Outcomes Study, Risk Education & Assessment for Cancer Heredity Project (REACH Project), and the Utah Cancer Survivors Study. Characteristics associated with lower odds of contact included Hispanic ethnicity (Odds Ratio [OR] = 0. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/aje/advance-article/doi/10.1093/aje
Publisher Site
http://dx.doi.org/10.1093/aje/kwz011DOI Listing
January 2019
5 Reads

A novel combined transoral and transcervical surgical approach for recurrent metastatic medullary thyroid cancer to the parapharyngeal space.

J Robot Surg 2019 Jan 28. Epub 2019 Jan 28.

Otolaryngology Head and Neck Surgery Department, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.

Medullary thyroid cancer (MTC) represents less than 1% of all thyroid cancers. Complete surgical resection remains the mainstay of treatment for locoregional disease. Unfortunately, patients with recurrence may present with metastasis to challenging anatomic locations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11701-019-00930-5DOI Listing
January 2019

MEN 2B masquerading as chronic blepharitis and euryblepharon.

Orbit 2019 Jan 27:1-5. Epub 2019 Jan 27.

c Ocular Pathology Department , Wills Eye Hospital , Philadelphia , PA , USA.

This is a retrospective case description of a single male patient found to have multiple endocrine neoplasia syndrome type 2B (MEN 2B). At the age of 14, he presented for evaluation of ocular irritation and eyelid thickening. Intraoperative assessment revealed mucosal lesions on the anterior dorsum of his tongue and biopsy of multiple eyelid lesions disclosed bilateral submucosal neuromas, leading to the diagnosis of MEN 2B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01676830.2019.1567800DOI Listing
January 2019
1 Read

Ga-DOTANOC and F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers.

Endocrine 2019 Jan 25. Epub 2019 Jan 25.

Nuclear Medicine Department, Instituto Português de Oncologia do Porto, Porto, Portugal.

Objective: Metastatic disease is common in medullary thyroid carcinoma (MTC) and it is usually detected by raising calcitonin and carcinoembryonic antigen (CEA) levels. Nuclear medicine imaging has an important role in lesion identification/characterisation. We aim to compare Ga-DOTANOC PET/CT and F-FDG PET/CT performance and to explore the correlations between tumoral markers and functional imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-01846-8DOI Listing
January 2019
1 Read

Medullary Thyroid Carcinoma: Why Is Specialization Mandatory?

Authors:
Theresia Weber

Visc Med 2018 Dec 17;34(6):419-421. Epub 2018 Nov 17.

Department of Endocrine Surgery, Katholisches Klinikum, Mainz, Germany.

Medullary thyroid carcinoma (MTC) represents a distinct form of thyroid cancer with a potentially aggressive behavior, early lymph node metastases, and sporadic as well as hereditary forms. Only surgery with total thyroidectomy and lymph node dissection is able to achieve biochemical cure. Due to the uncommon nature of MTC, a specialization in endocrine surgery for diagnosis as well as therapy of MTC seem to be mandatory for a successful treatment. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/493809
Publisher Site
http://dx.doi.org/10.1159/000493809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341351PMC
December 2018
4 Reads

Expression profile and biological function of miR-455-5p in colorectal carcinoma.

Oncol Lett 2019 Feb 21;17(2):2131-2140. Epub 2018 Dec 21.

Department of Breast Surgery, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China.

Underexpression of microRNA-455-5p (miR-455-5p) in medullary thyroid carcinoma, melanoma, gastric cancer and additional cancer types has been reported, which may be associated with carcinoma development. The present study aimed to evaluate the expression profile and biological role of miR-455-5p in colorectal carcinoma. Carcinoma tissues and adjacent tissue specimens from 40 patients with colorectal cancer were randomly collected. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9862
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341642PMC
February 2019
6 Reads

Completeness of testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study.

Clin Epidemiol 2019 10;11:93-99. Epub 2019 Jan 10.

Department of ORL Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark,

Background: The completeness of arranged during ransfection () testing in patients with medullary thyroid carcinoma (MTC) was recently reported as 60%. However, the completeness on a population level is unknown. Similarly, it is unknown if the first Danish guidelines from 2002, recommending testing in all MTC patients, improved completeness in Denmark. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CLEP.S183268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330966PMC
January 2019
1 Read

Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.

Lancet Diabetes Endocrinol 2019 Mar 16;7(3):213-220. Epub 2019 Jan 16.

Endocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.

Background: Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22138587183033
Publisher Site
http://dx.doi.org/10.1016/S2213-8587(18)30336-XDOI Listing
March 2019
6 Reads

The role of ultrasound in the diagnosis of the coexistence of primary hyperparathyroidism and non-medullary thyroid carcinoma.

BMC Med Imaging 2019 01 18;19(1). Epub 2019 Jan 18.

Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Institute of Ultrasound in Medicine, 600 Yishan Road, Shanghai, 200233, China.

Background: The coexistence of primary hyperparathyroidism(PHPT) and papillary thyroid cancer(PTC) is a known entity; it is a rare and complicated setting for diagnostic imaging.

Methods: After reviewing clinical data of 112 patients who had been treated for PHPT in our facility between January 2015 and December 2017, we identified 7 non-medullary thyroid carcinoma (NMTC) (6.25%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12880-019-0306-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339388PMC
January 2019
3 Reads
0.983 Impact Factor

miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma.

Oncol Lett 2019 Jan 26;17(1):372-378. Epub 2018 Oct 26.

Department of Nuclear Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China.

Previous studies indicate that miR-149 could both inhibit and promote the development of human cancer depending on the tumor type. GIT1 was found to play an important role in regulating cell migration. However, the specific function of miR-149-5p and GIT1 in the progression of medullary thyroid carcinoma (MTC) remains unknown. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9628
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313157PMC
January 2019
3 Reads

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.

Pharmaceuticals (Basel) 2019 Jan 15;12(1). Epub 2019 Jan 15.

Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

The high overexpression of cholecystokinin-2 receptors (CCK2R) in tumors, such as medullary thyroid carcinoma, allows for highly specific diagnostic and therapeutic targeting with radiolabeled peptide probes derived from natural ligands for the receptor. Based on the ideal imaging characteristics, high availability and low cost of technetium-99m (Tc)-labeled radiopharmaceuticals we have developed two hydrazinonicotinic acid (HYNIC) conjugated minigastrin analogs allowing labeling at high specific activity. The CCK2R targeting peptide conjugates show specific amino acid substitutions in the C-terminal receptor-specific sequence with the aim to increase stability and tumor targeting. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1424-8247/12/1/13
Publisher Site
http://dx.doi.org/10.3390/ph12010013DOI Listing
January 2019
5 Reads

Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: A National Cohort Study.

J Surg Oncol 2019 Jan 15. Epub 2019 Jan 15.

Department of ORL, Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.

Background And Objectives: Recently, a comprehensive study presented evidence that a long-disputed REarranged during Transfection (RET) variant, RET Y791F, should be classified as nonpathogenic. In spite of this, several subsequently published papers, including the revised American Thyroid Association guidelines for medullary thyroid carcinoma, refer to the variant as pathogenic. This study presents data from a unique national Danish cohort of RET Y791F carriers who have been followed by watchful waiting instead of being subjected to early thyroidectomy, to determine if any carrier shows evidence of multiple endocrine neoplasia 2A (MEN2A) at long-term follow-up. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.25371
Publisher Site
http://dx.doi.org/10.1002/jso.25371DOI Listing
January 2019
6 Reads

Familial and Hereditary Forms of Primary Hyperparathyroidism.

Front Horm Res 2019 19;51:40-51. Epub 2018 Nov 19.

Individuals with a familial predisposition to the development of parathyroid tumors constitute a small minority of all patients with primary hyperparathyroidism (PHPT). These familial syndromes exhibit Mendelian inheritance patterns and the main causative genes in most families have been identified. They include multiple endocrine neoplasia (MEN; types 1, 2A, and 4), hyperparathyroidism-jaw tumor (HPT-JT) syndrome, familial isolated hyperparathyroidism, familial hypocalciuric hypercalcemia (FHH), and neonatal severe PHPT. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/491037
Publisher Site
http://dx.doi.org/10.1159/000491037DOI Listing
November 2018
3 Reads

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.

Future Oncol 2019 Jan 14. Epub 2019 Jan 14.

Department of Head & Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.

Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0557DOI Listing
January 2019
2 Reads

Rare complications of multikinase inhibitor treatment.

Arch Endocrinol Metab 2018 ;62(6):636-640

Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina.

Objective: The advent of multikinase inhibitor (MKI) therapy has led to a radical change in the treatment of patients with advanced thyroid carcinoma. The aim of this manuscript is to communicate rare adverse events that occurred in less than 5% of patients in clinical trials in a subset of patients treated in our hospital.

Subjects And Methods: Out of 760 patients with thyroid cancer followed up with in our Division of Endocrinology, 29 (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20945/2359-3997000000090DOI Listing
February 2019
6 Reads

A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.

Arch Endocrinol Metab 2018 ;62(6):623-635

Centro de Doenças da Tiroide e Laboratório de Endocrinologia Molecular e Translacional, Divisão de Endocrinologia, Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-Unifesp), São Paulo, SP, Brasil.

Objective: Initial diagnosis of medullary thyroid carcinoma (MTC) is frequently associated with advanced stages and a poor prognosis. Thus, the need for earlier diagnoses and detection in relatives at risk for the disease has led to increased use of RET genetic screening.

Subjects And Methods: We performed RET screening in 247 subjects who were referred to the Brazilian Research Consortium for Multiple Endocrine Neoplasia (BRASMEN) Center in the State of Ceará. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20945/2359-3997000000088DOI Listing
February 2019
1 Read

Survival and Long-Term Biochemical Cure in Medullary Thyroid Carcinoma in Denmark 1997-2014: A Nationwide Study.

Thyroid 2019 Jan 31. Epub 2019 Jan 31.

1 Department of ORL-Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.

Background: Survival of medullary thyroid carcinoma (MTC) subgroups in relation to the general population is poorly described. Data on the factors predicting long-term biochemical cure in MTC patients are nonexistent at a population level. A nationwide retrospective cohort study of MTC in Denmark from 1997 to 2014 was conducted, aiming to detect subgroups with survival similar to that of the general population and to identify prognostic factors for disease-specific survival and long-term biochemical cure. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2018.0564
Publisher Site
http://dx.doi.org/10.1089/thy.2018.0564DOI Listing
January 2019
8 Reads

Prognostic value of numbers of metastatic lymph node in medullary thyroid carcinoma: A population-based study using the SEER 18 database.

Medicine (Baltimore) 2019 Jan;98(1):e13884

Department of Thyroid and Breast Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Road.

Lymph node (LN) metastases are widely considered as a vital assessment of disease progression, as well as an essential indicator for biochemical cure of medullary thyroid carcinoma (MTC). Prognostic effect of numbers of metastatic LN has not been fully studied and the optimal cut-point of LN numbers has not been established. This population-based study designed to investigate prognostic value of numbers of positive LN and determinate the prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013884DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344130PMC
January 2019
1 Read

Coexistence of a large functioning parathyroid cyst with papillary thyroid carcinoma: A case report and review of the literature.

Case Rep Womens Health 2019 Jan 30;21:e00091. Epub 2018 Nov 30.

Department of Endocrinology and Diabetes, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece.

Parathyroid cysts constitute a rare cause of primary hyperparathyroidism (PHPT). PHPT may also rarely coexist with non-medullary thyroid carcinoma (NMTC). We describe a case of a 70-year-old woman who was diagnosed with PHPT, on the occasion of nephrolithiasis (corrected calcium and PTH levels: 10. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22149112183014
Publisher Site
http://dx.doi.org/10.1016/j.crwh.2018.e00091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305791PMC
January 2019
4 Reads

An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature.

Endocr Metab Immune Disord Drug Targets 2019 ;19(2):226-229

Endocrinology and Metabolism Unit, University-Hospital "Santa Maria della Misericordia", Udine, Italy.

Background: Medullary thyroid cancer (MTC) accounts for 5% of all thyroid cancers and occurs either sporadically or in a hereditary pattern. Routine calcitonin (CT) measurement is suggested for MTC screening in patients with nodular thyroid disease.

Patient Findings: A 45 years-old woman incidentally discovered, with neck ultrasound, the presence of thyroid micronodules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871530319666181220165350DOI Listing
January 2019
3 Reads

Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials.

Eur Thyroid J 2018 Nov 16;7(6):308-312. Epub 2018 Aug 16.

Division of Endocrinology, University of Calgary, Calgary, Alberta, Canada.

Cabozantinib and lenvatinib have been approved for the treatment of progressive medullary thyroid cancer and radioiodine-resistant thyroid cancer, respectively. Both phase III trials of cabozantinib and lenvatinib reported that renal adverse events (AEs) rarely occurred. The cabozantinib phase III study reported no AEs related to renal toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276742PMC
November 2018
1 Read

Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.

Clin Nucl Med 2019 Mar;44(3):194-200

From the PET Unit, Department of Nuclear Medicine-IDI, and Departments of.

Objective: Medullary thyroid carcinoma (MTC) is a rare malignancy. Location of residual, recurrent, or metastatic disease is crucial to treatment management and outcome. We aimed to evaluate the use of F-FDG PET/CT in localizing MTC foci in patients with biochemical relapse. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00003072-900000000-9731
Publisher Site
http://dx.doi.org/10.1097/RLU.0000000000002414DOI Listing
March 2019
7 Reads

Benign call rate and molecular test result distribution of ThyroSeq v3.

Cancer Cytopathol 2018 Dec 18. Epub 2018 Dec 18.

Department of Pathology, University of Pittsburgh Medical Center-Presbyterian, Pittsburgh, Pennsylvania.

Background: The benign call rate (BCR) is the percentage of cytomorphologically indeterminate cases with subsequent benign or negative molecular results. For rule-out tests, the BCR is an important parameter because these molecular "negative" cases may be managed similarly to those with a benign cytology diagnosis. Although earlier versions of ThyroSeq molecular tests were less effective in excluding malignancy, the extensively expanded v3 version with a high negative predictive value is considered to represent a rule-out test. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncy.22088
Publisher Site
http://dx.doi.org/10.1002/cncy.22088DOI Listing
December 2018
9 Reads

[A misleading breast metastasis of medullary thyroid carcinoma].

Ann Pathol 2019 Feb 12;39(1):9-13. Epub 2018 Dec 12.

Université Paris Diderot, Sorbonne-Paris-Cité, 10, avenue de Verdun, 75010 Paris, France; Service d'anatomie et cytologie pathologiques, CHU Saint-Louis, AP-HP, Paris, France.

Recognition of mammary metastases by pathologists is fundamental because their prognosis and treatment are different from those of primary mammary carcinomas. We report the case of a 54-year-old woman presenting on her mammography a left breast nodule known for 5 years, having discreetly increased in size. Breast ultrasound showed a regular 1. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02426498183011
Publisher Site
http://dx.doi.org/10.1016/j.annpat.2018.07.004DOI Listing
February 2019
2 Reads

Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Mol Cancer Res 2018 Dec 14. Epub 2018 Dec 14.

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Medullary thyroid carcinoma (MTC) originates from the C cells of the thyroid gland, which secrete calcitonin. Lymph node and distant metastases are frequently present at diagnosis. Activating mutations of , a driver oncogene in MTC that encodes a tyrosine kinase receptor, prevents apoptosis through inhibition of ATF4, a key transcriptional regulator of endoplasmic reticulum (ER) stress. Read More

View Article

Download full-text PDF

Source
http://mcr.aacrjournals.org/lookup/doi/10.1158/1541-7786.MCR
Publisher Site
http://dx.doi.org/10.1158/1541-7786.MCR-18-0354DOI Listing
December 2018
10 Reads

Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study.

Endocr Connect 2019 Jan;8(1):1-7

Department of ORL Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.

A recent study proposed new TNM groupings for better survival discrimination among stage groups for medullary thyroid carcinoma (MTC) and validated these groupings in a population-based cohort in the United States. However, it is unknown how well the groupings perform in populations outside the United States. Consequently, we conducted the first population-based study aiming to evaluate if the recently proposed TNM groupings provide better survival discrimination than the current American Joint Committee on Cancer (AJCC) TNM staging system (seventh and eighth edition) in a nationwide MTC cohort outside the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330714PMC
January 2019
1 Read

[The patterns of cervical lymph node metastasis and the surgical treatment for untreated medullary thyroid carcinoma].

Authors:
L S Jin

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018 Oct;32(19):1504-1506

Department of Head and Neck Surgery, Tumar Hospital of Shanxi Province, 030013, China.

To study the features of cervical lymph node metastasis and the optimal type of surgical treatment for untreated medullary thyroid carcinoma. To retrospectively analyze the clinical data of 45 patients with untreated medullary thyroid carcinoma who received surgical treatment in our hospital. The patterns of cervical lymph node metastasis and the surgical treatment were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13201/j.issn.1001-1781.2018.19.016DOI Listing
October 2018
1 Read

Different outcomes in sporadic versus familial medullary thyroid cancer.

Head Neck 2019 Jan 11;41(1):154-161. Epub 2018 Dec 11.

Endocrine Unit, Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.

Background: Medullary thyroid carcinoma (MTC) has varying clinical course with familial cases (fMTC) diagnosed earlier than sporadic MTC (spMTC).

Methods: A total of 273 MTCs (familial: n = 110 [40.3%], males: 38. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hed.25463
Publisher Site
http://dx.doi.org/10.1002/hed.25463DOI Listing
January 2019
6 Reads

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

J Natl Compr Canc Netw 2018 Dec;16(12):1429-1440

Dana-Farber/Brigham and Women's Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; University of Washington/Seattle Cancer Care Alliance; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; Fox Chase Cancer Center; Fred & Pamela Buffett Cancer Center; University of Michigan Rogel Cancer Center; UC San Diego Moores Cancer Center; Huntsman Cancer Institute at the University of Utah; Stanford Cancer Institute; City of Hope National Medical Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Roswell Park Comprehensive Cancer Center; Moffitt Cancer Center; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute; Duke Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Wisconsin Carbone Cancer Center; Mayo Clinic Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; and National Comprehensive Cancer Network.

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for V600E-mutated anaplastic thyroid carcinoma. Read More

View Article

Download full-text PDF

Source
http://www.jnccn.org/lookup/doi/10.6004/jnccn.2018.0089
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.0089DOI Listing
December 2018
12 Reads
4.178 Impact Factor

HATRICK-Synchronous Triple Primary Tumors of Thyroid.

Indian J Surg Oncol 2018 Dec 18;9(4):592-594. Epub 2018 May 18.

3Department of Pathology, St. John's Medical College and Hospital, Bengaluru, Karnataka India.

Multiple primary cancer (MPC) has an incidence of 1.8% and is defined as having two or more cancers in a single patient. Synchronous tumors are defined as ≥ 2 primary tumors occurring within 6 months of diagnosis of the first primary tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13193-018-0772-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265187PMC
December 2018
3 Reads

DOTA-MGS5, a new cholecystokinin-2 receptor targeting peptide analog with optimized targeting profile for theranostic use.

J Nucl Med 2018 Dec 7. Epub 2018 Dec 7.

Department of Nuclear Medicine, Medical University of Innsbruck, Austria.

Molecular imaging and targeted radiotherapy (TRT) with radiolabeled cholecystokinin-2-receptor (CCK2R) targeting peptide probes holds high promise to improve the clinical management of patients with metastatic medullary thyroid carcinoma (MTC) and other CCK2R-expressing malignancies. Low stability and suboptimal targeting of currently available radiolabeled peptide analogs has prompted us to seek for new stabilization strategies. In this study we present a new minigastrin analog with site-specific C-terminal modifications showing a highly optimized targeting profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.118.221283DOI Listing
December 2018
1 Read

PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.

Eur J Surg Oncol 2019 Mar 21;45(3):353-358. Epub 2018 Oct 21.

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. Electronic address:

Introduction: Few studies have focused on PD-L1 expression in medullary thyroid carcinoma (MTC). Expressions of PD-1 and PD-L1 and their clinicopathologic and prognostic relevance were therefore further investigated on a relatively large population of MTC patients.

Materials And Methods: Surgical specimens were obtained from 87 MTC patients during a median follow-up of 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.10.060DOI Listing
March 2019
1 Read

Persistent disease and recurrence in medullary thyroid carcinoma: A case series.

Cir Esp 2018 Oct 25. Epub 2018 Oct 25.

Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario Insular de Gran Canaria, Universidad de las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ciresp.2018.08.008DOI Listing
October 2018
4 Reads

Understanding Malignancies of the Thyroid Gland: Institutional Experience.

Indian J Otolaryngol Head Neck Surg 2018 Dec 5;70(4):482-489. Epub 2018 Sep 5.

1Department of Otolaryngology and Head Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

To study the epidemiological, pathological characters and determine survival in patients diagnosed of having thyroid gland malignancies. Retrospective chart review of patients having thyroid gland malignancies, which were managed by the two senior authors at our tertiary care institute from January 2000 to December 2006, were performed and evaluated in terms of various clinical, operative and histological parameters. Patients in which follow up of at least 10 years are available were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12070-018-1492-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224818PMC
December 2018
8 Reads

Medullary thyroid carcinoma with breast metastasis: Two case reports.

Medicine (Baltimore) 2018 Nov;97(47):e13193

Department of Surgical Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.

Rationale: Medullary thyroid carcinoma (MTC) is an aggressive subtype of thyroid cancer with frequent hematogenous metastasis. While its metastasis is usually observed in the lung, liver, or bone, it rarely migrates to the breast.

Patient Concerns: Here we report 2 cases with a complaint of breast lump after initial treatment of MTC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013193DOI Listing
November 2018
7 Reads

The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma - What Cut-off Values Should We Use?

Clin Oncol (R Coll Radiol) 2019 Feb 17;31(2):e11-e20. Epub 2018 Nov 17.

Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong, China.

Aims: Recently published international guidelines recommended using the stimulated thyroglobulin (sTg) post-radioactive iodine (RAI) ablation, in conjunction with tumour stage, as a risk stratification factor. The choice of cut-off values for sTg, namely 1 and 10 ng/ml, was, however, largely based on the functional sensitivities of the assays used, with relatively few published data addressing the prognostic impact of alternative cut-off values. Our study aims to provide data on the prognostic value of sTg at different levels of sensitivities and specificities. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09366555183047
Publisher Site
http://dx.doi.org/10.1016/j.clon.2018.10.009DOI Listing
February 2019
15 Reads